Loading...
The manufacturer-sponsored, randomized, placebo-controlled JUPITER trial of rosuvastatin (20 mg/day) for prevention of coronary disease (JW Cardiol Nov 10 2008) included a prespecified analysis of the drug’s effect on incident venous thromboembolism (VTE, including pulmonary embolism and deep venous thrombosis). The study population comprised 17,802 healthy men and women with LDL levels <130 mg/dL and elevated C-reactive protein levels.
During a median follow-up of 1.9 years, the rates of symptomatic VTE were 0.18 and 0.32 events per 100 person-years in the rosuvastatin and placebo groups, respectively (P=0.007), amounting to one occurrence of VTE averted for every 714 patients treated with rosuvastatin for 1 year. The cumulative-incidence c…